A UPAR (UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR)-TARGETING CONJUGATE

The present invention describes a uPAR (urokinase Plasminogen Activator Receptor)-targeting conjugate comprising: -a fluorophore; -a molecule binding to the receptor; and-a linker group which covalently links the fluorophore to the molecule binding to the receptor, said linker group either being par...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HARTVIG, Line, ALBRECHTSEN, Morten, NØRSKOV RASMUSSEN, Grethe
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention describes a uPAR (urokinase Plasminogen Activator Receptor)-targeting conjugate comprising: -a fluorophore; -a molecule binding to the receptor; and-a linker group which covalently links the fluorophore to the molecule binding to the receptor, said linker group either being part of the molecule binding to the receptor or being a separate component of the uPAR (urokinase Plasminogen Activator Receptor)-targeting conjugate; wherein the uPAR (urokinase Plasminogen Activator Receptor)-targeting conjugate has a pharmacokinetic profile where a human TBR (tumor-to-background ratio) of at least 1.1 is reached within 3.5 hours post administration and where a human TBR of at least 1.5 is maintained at least 30 minutes before decreasing below 1.5, and wherein the uPAR-targeting conjugate is a human uPAR-targeting conjugate.